ConductScience.org, home

Paper42350656

TRIM32-mediated ABI2 downregulation promotes anoikis resistance and metastasis by regulating EMT in lung adenocarcinoma.

Liu Y and 3 others. Cell Mol Life Sci, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. TRIM32-mediated ABI2 downregulation promotes anoikis resistance and metastasis by regulating EMT in lung adenocarcinoma. Papers, record 42350656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42350656

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
TRIM32-mediated ABI2 downregulation promotes anoikis resistance and metastasis by regulating EMT in lung adenocarcinoma.
PubMed
Journal
Cell Mol Life Sci
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-16
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu YYongting
2Jiang ZZhaohui
3Zhao YYulong
4Chen QQionghttps://orcid.org/0009-0001-5577-8202

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnoikisMajor topic
Lung NeoplasmsMajor topic
Ubiquitin-Protein LigasesMajor topic
Tripartite Motif ProteinsMajor topic
Adenocarcinoma of LungMajor topic
Epithelial-Mesenchymal TransitionMajor topic
Adaptor Proteins, Signal TransducingMajor topic
Humans
Animals
Down-Regulation
Ubiquitination
Gene Expression Regulation, Neoplastic
Cell Line, Tumor
Mice, Nude
Neoplasm Metastasis
Mice
Female
Male
Mice, Inbred BALB C
Transcription Factors

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82370055National Natural Science Foundation of ChinaPubMed
2020YFC2008600Key Technologies Research and Development ProgramPubMed
Lung Cancer, ID: z027002National Multidisciplinary Cooprative Diagnosis and Treatment Capacity Building Project for Major DiseasesPubMed
2025ZZTS0238Fundamental Research Funds for the Central Universities of Central South UniversityPubMed
CX20250358Hunan Provincial Innovation Foundation for PostgraduatePubMed

Source PubMed

Download CSV of grants

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138994085Mitochondrial dysfunction significantly contributes to the sensitivity of tumor cells to anoikis and their metastatic potential.Heliyon2024https://conductscience.org/library/papers/38994085PubMed
238937761Inhibition of ABI2 ubiquitination-dependent degradation suppresses TNBC cell growth via down-regulating PI3K/Akt signaling pathway.Cancer Cell Int2024https://conductscience.org/library/papers/38937761PubMed
329665353Tripartite motif 31 promotes resistance to anoikis of hepatocarcinoma cells through regulation of p53-AMPK axis.Exp Cell Res2018https://conductscience.org/library/papers/29665353PubMed
440350473Digoxin promotes anoikis of circulating cancer cells by targeting Na+/K+-ATPase α3-isoform.Cell Death Dis2025https://conductscience.org/library/papers/40350473PubMed
530378152Expression and the potential functions of TRIM32 in lung cancer tumorigenesis.J Cell Biochem2019https://conductscience.org/library/papers/30378152PubMed
620493758ABA perception and signalling.Trends Plant Sci2010https://conductscience.org/library/papers/20493758PubMed
730464531TRIM32 overexpression improves chemoresistance through regulation of mitochondrial function in non-small-cell lung cancers.Onco Targets Ther2018https://conductscience.org/library/papers/30464531PubMed
840186594Novel therapeutic approaches for non-small cell lung cancer: an updated view.J Drug Target2025https://conductscience.org/library/papers/40186594PubMed
940294841Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding.Cancer Lett2025https://conductscience.org/library/papers/40294841PubMed
1039654601Exploring the Mechanisms, Biomarkers, and Therapeutic Targets of TRIM Family in Gastrointestinal Cancer.Drug Des Devel Ther2024https://conductscience.org/library/papers/39654601PubMed
1135589677TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways.Cell Death Dis2022https://conductscience.org/library/papers/35589677PubMed
1236230714Anoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies.Cancers (Basel)2022https://conductscience.org/library/papers/36230714PubMed
1331907338Downregulation of ABI2 expression by EBV-miR-BART13-3p induces epithelial-mesenchymal transition of nasopharyngeal carcinoma cells through upregulation of c-JUN/SLUG signaling.Aging (Albany NY)2020https://conductscience.org/library/papers/31907338PubMed
1436427397CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis.Redox Biol2022https://conductscience.org/library/papers/36427397PubMed
1533207810Emerging Concepts of Hybrid Epithelial-to-Mesenchymal Transition in Cancer Progression.Biomolecules2020https://conductscience.org/library/papers/33207810PubMed
1637344626Epigenetic regulation of hybrid epithelial-mesenchymal cell states in cancer.Oncogene2023https://conductscience.org/library/papers/37344626PubMed
1735719027PRR16/Largen Induces Epithelial-Mesenchymal Transition through the Interaction with ABI2 Leading to the Activation of ABL1 Kinase.Biomol Ther (Seoul)2022https://conductscience.org/library/papers/35719027PubMed
1839895782Training and experimental validation a novel anoikis- and epithelial‒mesenchymal transition-related signature for evaluating prognosis and predicting immunotherapy efficacy in gastric cancer.J Cancer2025https://conductscience.org/library/papers/39895782PubMed
1918632609Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2.Cancer Res2008https://conductscience.org/library/papers/18632609PubMed
2039389179GDF15 enhances anoikis resistance and metastasis of gastric cancer through protective autophagy.Cell Signal2024https://conductscience.org/library/papers/39389179PubMed

See all 42 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABI210152PubTator's text mininghttps://conductscience.org/library/genes/10152NCBI Gene
TRIM3222954PubTator's text mininghttps://conductscience.org/library/genes/22954NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42350656

GET https://conductscience.org/api/papers/v1/42350656/references?page=2